Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Sight Sciences Posts Long-Term Safety, Effectiveness Data For Glaucoma Surgical System

Sight Sciences Inc (NASDAQ: SGHT) announced 36-month post-surgery follow-up results of the OMNI Surgical System.  The data demonstrates that the OMNI Surgical…
byVandana Singh
August 16, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Sight Sciences Inc (NASDAQ: SGHT) announced 36-month post-surgery follow-up results of the OMNI Surgical System. 
  • The data demonstrates that the OMNI Surgical System delivers safe, consistent, and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basis.
  • The study showed that canaloplasty followed by trabeculectomy using the OMNI Surgical System achieved a mean reduction in intraocular pressure (IOP) of at least 20% for all 26 patients (38 eyes) at 36 months follow-up. 
  • The post-operative IOP and medication use reduction at 12 months remained consistent over three years, suggesting robust, durable effectiveness of the OMNI Surgical System. 
  • A minimal number of adverse events were reported, all resolved without intervention except one eye required secondary IOP lowering intervention.
  • Price Action: SGHT shares are down 2.86% at $8.51 during the market session on the last check Tuesday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Standard General Issues Statement On Acquisition Of TEGNA; Responding To Authorities Says Committed To Waive Certain Contractual Rights Co. Would Have Had As Result Of Transaction To Demonstrate Public Interest Benefits Of Transaction

By Michael Horton
December 16, 5:30 PM
Standard General L.P. today issued the following statement regarding its pending acquisition of TEGNA Inc. (NYSE:TGNA): "Our proposed acquisition of TEGNA has been the subject of regulatory review that continues

TGNA